Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer

Huggins, C.; Hodges, C.V. Studies on prostatic cancer i. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1941, 1(4), 293-297.
[http://dx.doi.org/10.3322/canjclin.22.4.232] [PMID: 4625049]

Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; Petrylak, D.; Kantoff, P.; Basch, E.; Kelly, W.K.; Figg, W.D.; Small, E.J.; Beer, T.M.; Wilding, G.; Martin, A.; Hussain, M. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. J. Clin. Oncol., 2008, 26(7), 1148-1159.
[http://dx.doi.org/10.1200/JCO.2007.12.4487] [PMID: 18309951]

Shiota, M.; Eto, M. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int. J. Urol., 2016, 23(5), 360-369.
[http://dx.doi.org/10.1111/iju.13091] [PMID: 27062039]

Saad, F.; Efstathiou, E.; Attard, G.; Flaig, T.W.; Franke, F.; Goodman, O.B., Jr; Oudard, S.; Steuber, T.; Suzuki, H.; Wu, D.; Yeruva, K.; De Porre, P.; Brookman-May, S.; Li, S.; Li, J.; Thomas, S.; Bevans, K.B.; Mundle, S.D.; McCarthy, S.A.; Rathkopf, D.E. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol., 2021, 22(11), 1541-1559.
[http://dx.doi.org/10.1016/S1470-2045(21)00402-2] [PMID: 34600602]

Maluf, F.C.; Schutz, F.A.; Cronemberger, E.H.; Luz, M.A.; Martins, S.P.S.; Muniz, D.Q.B.; Bastos, D.A.; Cárcano, F.M.; Smaletz, O.; Soares, A.; Peixoto, F.A.; Gomes, A.J.; Cruz, F.M.; Franke, F.A.; Herchenhorn, D.; dos Santos, T.M.; Fabricio, V.C.; Gidekel, R.; Werutsky, G.; de Jesus, R.G.; Souza, V.C.; Fay, A.P. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur. J. Cancer, 2021, 158, 63-71.
[http://dx.doi.org/10.1016/j.ejca.2021.08.032] [PMID: 34655838]

Attard, G.; Murphy, L.; Clarke, N.W.; Cross, W.; Jones, R.J.; Parker, C.C.; Gillessen, S.; Cook, A.; Brawley, C.; Amos, C.L.; Atako, N.; Pugh, C.; Buckner, M.; Chowdhury, S.; Malik, Z.; Russell, J.M.; Gilson, C.; Rush, H.; Bowen, J.; Lydon, A.; Pedley, I.; O’Sullivan, J.M.; Birtle, A.; Gale, J.; Srihari, N.; Thomas, C.; Tanguay, J.; Wagstaff, J.; Das, P.; Gray, E.; Alzoueb, M.; Parikh, O.; Robinson, A.; Syndikus, I.; Wylie, J.; Zarkar, A.; Thalmann, G.; de Bono, J.S.; Dearnaley, D.P.; Mason, M.D.; Gilbert, D.; Langley, R.E.; Millman, R.; Matheson, D.; Sydes, M.R.; Brown, L.C.; Parmar, M.K.B.; James, N.D.; Jones, E.; Hyde, K.; Glen, H.; Needleman, S.; McGovern, U.; Sheehan, D.; Paisey, S.; Shaffer, R.; Beresford, M.; Malik, Z.; Zarkar, A.; Porfiri, E.; Fackrell, D.; Lee, L.; Sreenivasan, T.; Brock, S.; Brown, S.; Bahl, A.; Smith-Howell, M.; Woodward, C.; Phan, M-D.; Mazhar, D.; Narahari, K.; Tanguay, J.; Douglas, F.; Kumar, A.; Hamid, A.; Ibrahim, A.; Muthukumar, D.; Simms, M.; Worlding, J.; Tran, A.; Kagzi, M.; Das, P.; Pezaro, C.; Sivoglo, V.; Masters, B.; Keng-Koh, P.; Manetta, C.; McLaren, D.; Gupta, N.; Sheehan, D.; Boussios, S.; Taylor, H.; Graham, J.; Perna, C.; Melcher, L.; Grant, W.; Hyde, K.; Sabharwal, A.; Hofmann, U.; Dealey, R.; McPhail, N.; Brierly, R.; Brown, S.; Capaldi, L.; Sidek, N.; Whelan, P.; Sreenivasan, T.; Robson, P.; Falconer, A.; Rudman, S.; Vivekanandan, S.; Mullessey, V.; Needleman, S.; Vilarino-Varela, M.; Khoo, V.; Tipples, K.; Afshar, M.; Falconer, A.; Brulinski, P.; Sangar, V.; Peedell, C.; Azzabi, A.; Hoskin, P.; Mullassery, V.; Sundar, S.; Khan, Y.; Conroy, R.; Protheroe, A.; Carser, J.; Rogers, P.; Capaldi, L.; Tarver, K.; Gibbs, S.; Khan, M.M.; Hingorani, M.; Azzabi, A.; Crabb, S.; Alameddine, M.; Bhalla, N.; Manetta, C.; Hughes, R.; Logue, J.; Leaning, D.; Vengalil, S.; Azzabi, A.; Ford, D.; Walker, G.; Shaheen, A.; Khan, O.; Chan, A.; Ahmed, I.; Hilman, S.; Douglas, F.; Kumar, A.; Tran, A.; Paisey, S.; Sayers, I.; Capaldi, L.; Nikapota, A.; Bloomfield, D.; Porter, T.; Joseph, J.; Rentsch, C.; Pereira Mestre, R.; Roggero, E.; Beyer, J.; Borner, M.; Strebel, R.; Berthold, D.; Engeler, D.; John, H.; Popescu, R.; Durr, D. Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 2022, 399(10323), 447-460.
[http://dx.doi.org/10.1016/S0140-6736(21)02437-5] [PMID: 34953525]

McKay, R.R.; Ye, H.; Xie, W.; Lis, R.; Calagua, C.; Zhang, Z.; Trinh, Q.D.; Chang, S.L.; Harshman, L.C.; Ross, A.E.; Pienta, K.J.; Lin, D.W.; Ellis, W.J.; Montgomery, B.; Chang, P.; Wagner, A.A.; Bubley, G.J.; Kibel, A.S.; Taplin, M.E. Evaluation of intense androgen deprivation before prostatectomy: A randomized Phase II trial of enzalutamide and leuprolide with or without abiraterone. J. Clin. Oncol., 2019, 37(11), 923-931.
[http://dx.doi.org/10.1200/JCO.18.01777] [PMID: 30811282]

Simon, I.; Perales, S.; Casado-Medina, L.; Rodríguez-Martínez, A.; Garrido-Navas, M.C.; Puche-Sanz, I.; Diaz-Mochon, J.J.; Alaminos, C.; Lupiañez, P.; Lorente, J.A.; Serrano, M.J.; Real, P.J. Cross‐resistance to abiraterone and enzalutamide in castration resistance prostate cancer cellular models is mediated by ar transcriptional reactivation. Cancers , 2021, 13(6), 1483.
[http://dx.doi.org/10.3390/cancers13061483] [PMID: 33807106]

Zhao, J.; Ning, S.; Lou, W.; Yang, J.C.; Armstrong, C.M.; Lombard, A.P.; D’Abronzo, L.S.; Evans, C.P.; Gao, A.C.; Liu, C. Cross-resistance among next-generation antiandrogen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer. Mol. Cancer Ther., 2020, 19(8), 1708-1718.
[http://dx.doi.org/10.1158/1535-7163.MCT-20-0015] [PMID: 32430485]

Wang, B.; Gu, Y.; Hui, K.; Huang, J.; Xu, S.; Wu, S.; Li, L.; Fan, J.; Wang, X.; Hsieh, J.T.; He, D.; Wu, K. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. Urol. Oncol., 2018, 36(10), 472.e11-472.e20.
[http://dx.doi.org/10.1016/j.urolonc.2018.07.005] [PMID: 30139661]

Saad, F.; Armstrong, F.A.; Thiery-Vuillemin, A.; Oya, M.; Loredo, E.; Procopio, G.; Janoski de Menezes, J.; Girotto, G.C.; Arslan, C.; Mehra, N.; Parnis, F.; Brown, E.; Schlürmann, F.; Young Joung, J.; Sugimoto, M.; Poehlein, C.H.; Harrington, E.; Desai, C.; Kang, J.; Clarke, N. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol., 2022, 40(Suppl. 6), 11.
[http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.011]

Chi, K.N.; Rathkopf, D.E.; Smith, M.R.; Efstathiou, E.; Attard, G.; Olmos, D.; Lee, J.Y.; Small, E.Y.; Gomes, A.Y.; Roubaud, G.; Saad, M.; Zurawski, B.; Sakalo, V.; Mason, G.; del Corral, A.; Wang, G.C.; Wu, D.; Diorio, B. Lopez- Gitlitz, A.M.; Sandhu, H.K. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. J. Clin. Oncol., 2022, 40(Suppl. 6), 12.

De Bono, J.S.; Sweeney, C.; Bracarda, S.; Sternberg, C.N.; Chi, K.N.; Olmos, D.; Sandhu, S.K.; Massard, C.; Matsubara, N.; Garcia, J.; Nowicka, M.; Wongchenko, M.; Shi, Z. PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer. J. Clin. Oncol., 2021, 39(Suppl. 6), 13.